Are You Failing Your HCT Recipients? A Case Study on CMV Prophylaxis - a podcast by ReachMD

CME credits: 0.25

Valid until: 28-02-2021

Claim your CME credit at https://reachmd.com/programs/cme/are-you-failing-your-hct-recipients-case-study-cmv-prophylaxis/11255/

Infection with cytomegalovirus (CMV) is a source of high morbidity and preventable mortality in hematopoietic stem cell transplant (HCT) recipients, and the risk of CMV reactivation is significant in allogeneic HSCT recipients. Fortunately, a new era of therapy has emerged, marked by the development of targeted treatments showing stronger efficacy over more traditional antiviral therapies. But what does the application of those therapies look like in action?

This activity will review the appropriate CMV pre-emptive therapy in patients undergoing HSCT as well as discuss the newer approaches to preventing CMV infection and how clinical practice guidelines and expert recommendations have changed regarding the role of prophylaxis in CMV seropositive recipients.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD